Histology – Page 7 – ScanLab Center

07 Jun

ADENOSINE DEAMINASE, CSF

June 7, 2023June 7, 2023vincentochiengde

Category

Routine Chemistry

Sub Category

Fluid Analysis

Synonym/Aliases

Ada, Cerebrospinal Fluid; Ada, Spinal Fluid

Abbreviations

ADA, CSF

^Type

INDIVIDUAL TEST

^Results

RESULTS READY WITHIN 5 WORING DAYS

^Method

ENZYMATIC

^Temp

AMBIENT: 2-3 HOURS; R (2-8℃): 7DAYS; F (-20℃): 14DAYS

^Setup

DAILY

Components Parameters

-Not Applicable

PRE-ANALYTIC CONSIDERATIONS

Test Ordering Instructions

FILL OUT TEST REQUEST FORM FULLY & LEGIBLY.

Patient preparation

-NOT APPLICABLE

Sample type

CSF

Container/ preservative

STERILE LEAK PROOF CONTAINER.

Sample volume

AT LEAST 2 ML.

Rejection criteria

LABELING ISSUE (UNLABELED/ MISLABELED); MISSING REQUEST FORM; MISMATCH BETWEEN REQUEST FORM & SAMPLE DETAILS; MISSING AGE/ GENDER; WRONG SAMPLE TYPE; INSUFFICIENT SAMPLE.

Other Instructions

- NOT APPLICABLE

Reference intervals

AGE & GENDER APPROPRIATE VALUES ARE PROVIDED ON THE REPORT

Clinical Utility

ANCILLARY TEST PRIMARILY USED IN EVALUATING FOR TUBERCULOSIS.

Test Limitations / Confounders

LEVELS MAY ALSO BE ELEVATED IN LIVER CIRRHOSIS, VIRAL HEPATITIS, AUTOIMMUNE DISEASES (SLE, RA), MALIGNANCIES (E.G. LYMPHOMAS)

07 Jun

ADENOSINE DEAMINASE, ASCITIC FLUID

June 7, 2023June 7, 2023vincentochiengde

Category

Routine Chemistry

Sub Category

Fluid Analysis

Synonym/Aliases

Adenosine Deaminase, Peritoneal Fluid

Abbreviations

ADA, ASCITIC FLUID

^Type

Individual Test

^Results

RESULTS READY WITHIN 5 WORING DAYS

^Method

ENZYMATIC

^Temp

AMBIENT: 2-3 HOURS; R (2-8℃): 7DAYS; F (-20℃): 14DAYS

^Setup

DAILY

Components Parameters

-Not Applicable

PRE-ANALYTIC CONSIDERATIONS

Test Ordering Instructions

FILL OUT TEST REQUEST FORM FULLY & LEGIBLY. FOR EXPECTANT CLIENTS ONLY.

Patient preparation

-NOT APPLICABLE

Sample type

ASCITIC FLUID

Container/ preservative

LEAK PROOF CONTAINER.

Sample volume

AT LEAST 3 ML.

Rejection criteria

LABELING ISSUE (UNLABELED/ MISLABELED); MISSING REQUEST FORM; MISMATCH BETWEEN REQUEST FORM & SAMPLE DETAILS; MISSING AGE/ GENDER; WRONG SAMPLE TYPE; INSUFFICIENT SAMPLE.

Other Instructions

- NOT APPLICABLE

Reference intervals

INTERPRETIVE DATA IS PROVIDED ON THE REPORT

Clinical Utility

ANCILLARY TEST PRIMARILY USED IN EVALUATING FOR TUBERCULOSIS.

Test Limitations / Confounders

LEVELS MAY ALSO BE ELEVATED IN LIVER CIRRHOSIS, VIRAL HEPATITIS, AUTOIMMUNE DISEASES (SLE, RA), MALIGNANCIES (E.G. LYMPHOMAS)

06 Jun

75g ORAL GLUCOSE TOLERANCE TEST, GESTATIONAL

June 6, 2023June 6, 2023vincentochiengde

Category

Molecular Genetic Pathology & Cytogenetics

Sub Category

Endocrine

Synonym/Aliases

75g Ogtt, Gestational

Abbreviations

N/A

^Type

profile/ panel (bundled tests)

^Results

RESULTS READY WITHIN 4 HOURS

^Method

SPECTROPHOTOMETRIC ENZYMATIC

^Temp

TEMPERATURE KEPT REFRIGIRATED

^Setup

DAILY

Components Parameters

0 hours, 1 hour post load, 2-3 hours post load glucose tests.

PRE-ANALYTIC CONSIDERATIONS

Test Ordering Instructions

FILL OUT TEST REQUEST FORM FULLY & LEGIBLY. FOR EXPECTANT CLIENTS ONLY.

Patient preparation

FASTING FOR AT LEAST 8 HOURS REQUIRED.

Sample type

FLUORIDE/ OXALATE PLASMA. MULTI-SAMPLING IS REQUIRED I.E. BASELINE FASTING SAMPLE; THEN 1 & 2 HOUR POST LOAD SAMPLES. SAMPLE LABELS MUST INCLUDE COLLECTION SEQUENCE E.G. 0 (BASELINE), 1HR, 2HR SAMPLE

Container/ preservative

FLUORIDE/ OXALATE (GREY TOP) VACUTAINER

Sample volume

AT LEAST 2ML

Rejection criteria

LABELING ISSUE (UNLABELED/ MISLABELED); MISSING REQUEST FORM; MISMATCH BETWEEN REQUEST FORM & SAMPLE DETAILS; MISSING AGE/ GENDER; WRONG SAMPLE TYPE; INSUFFICIENT SAMPLE; GROSS HEMOLYSIS; NONFASTING SAMPLES.

Other Instructions

URINE SAMPLES FOR URINE GLUCOSE TESTING ARE NOT ROUTINELY COLLECTED.

Reference intervals

AS PER THE LATEST AMERICAN DIABETIC ASSOCIATION CONSENSUS GUIDELINES.

Clinical Utility

SCREENING & DIAGNOSIS OF GESTATIONAL DIABETES MELLITUS (GDM)

Test Limitations / Confounders

-N/A

06 Jun

50g GLUCOSE LOADING TEST

June 6, 2023June 6, 2023vincentochiengde

Category

Routine Cemistry

Sub Category

Endocrine

Synonym/Aliases

O'sullivan Test

Abbreviations

N/A

^Type

profile/ panel (bundled tests)

^Results

RESULTS READY WITHIN 4 HOURS

^Method

SPECTROPHOTOMETRIC ENZYMATIC

^Temp

KEPT AT ROOM TEMPERATURE REFRIGIRATED

^Setup

DAILY

Components Parameters

0 hours (baseline), 1 hour post load glucose tests.

PRE-ANALYTIC CONSIDERATIONS

Test Ordering Instructions

FILL OUT TEST REQUEST FORM FULLY & LEGIBLY. FOR PREGNANT WOMEN ONLY

Patient preparation

NOT APPLICABLE. FASTING IS NOT A REQUIREMENT FOR THIS TEST.

Sample type

FLUORIDE/ OXALATE PLASMA. MULTI-SAMPLING IS REQUIRED I.E. BASELINE (PRE-LOAD) SAMPLE; THEN 1 HOUR POST LOAD SAMPLES. SAMPLE LABELS MUST INCLUDE COLLECTION SEQUENCE E.G. 0 (BASELINE), 1HR SAMPLE

Container/ preservative

FLUORIDE/ OXALATE (GREY TOP) VACUTAINER

Sample volume

AT LEAST 1ML FLUORIDE/ OXALATE PLASMA EACH

Rejection criteria

Other Instructions

URINE SAMPLES FOR URINE GLUCOSE TESTING ARE NOT ROUTINELY COLLECTED.

Reference intervals

AS PER THE LATEST AMERICAN DIABETIC ASSOCIATION CONSENSUS GUIDELINES.

Clinical Utility

TO SCREEN FOR GESTATIONAL DIABETES.

Test Limitations / Confounders

-N/A

06 Jun

SARS-CoV-2 PCR, QUALITATIVE

June 6, 2023June 6, 2023vincentochiengde

Category

Molecular Genetic Pathology & Cytogenetics

Sub Category

Infectious Disease

Synonym/Aliases

Covid-19 Rt-pcr

Abbreviations

Covid PCR

^Type

Individual Test

^Results

RESULTS READY WITHIN 24 HOURS

^Method

REAL TIME REVERSE TRANSCRIPTION PCR (RT-PCR) FOR DETECTION OF SARS-CoV-2 NUCLEIC ACID (RNA).

^Temp

REFRIGERATED, 2-8ºC (48-72 HOURS); FROZEN (>72 HOURS)

^Setup

DAILY

Components Parameters

- N/A

PRE-ANALYTIC CONSIDERATIONS

Test Ordering Instructions

FILL OUT TEST REQUEST FORM FULLY & LEGIBLY. SARS-CoV-2 CASE INVESTIGATION FORM WILL NEED TO BE FILLED OUT IN ENTIRETY TO FULFILL MOH/ NATIONAL REPORTING REQUIREMENTS.

Patient preparation

- N/A

Sample type

NASOPHARYNGEAL (NP) &/ OR OROPHARYNGEAL (OP) SWAB COLLECTED USING DRAYON, RAYON OR POLYESTER FIBRE SWABS, PLACED IN VIRAL TRANSPORT MEDIA (VTM) & WELL CAPPED. SAMPLES MUST BE LABELED WITH PATIENT NAME, OTHER UNIQUE IDENTIFIER, SAMPLE TYPE(S) & COLLECTION DATE. THEY MUST BE ACCOMPANIED BY A LAB REQUISITION AND A LEGIBLE AND FULLY FILLED COVID-19 CASE INVESTIGATION FORM. SAMPLES ARE TRIPLE PACKAGED AND IMMEDIATELY DELIVERED/ TRANSPORTED WITH FROZEN GEL PACKS.

Container/ preservative

NP &/ OR OP SWAB IN VIRAL TRANSPORT MEDIUM (VTM).

Sample volume

- N/A

Rejection criteria

LABELING ISSUE (UNLABELED/ MISLABELED); MISSING REQUEST FORM; MISMATCH BETWEEN REQUEST FORM & SAMPLE DETAILS; MISSING AGE/ GENDER; WRONG SAMPLE TYPE; INSUFFICIENT SAMPLE.

Other Instructions

CALCIUM AGINATE, COTTON SWABS OR SWABS WITH WOODEN STICKS CAN INHIBIT PCR RESULTING IN FALSE NEGATIVE RESULTS. SAMPLES COLLECTED USING THESE WILL NOT BE ACCEPTED/ PROCESSED. SAMPLES WITHOUT A COMPLETED COVID-19 CASE INVESTIGATION FORM WILL BE PUT ON HOLD AND NOT PROCESSED. INFORMATION CAPTURED ON THE FORM IS MANDATORY WHEN REPORTING TO A) THE NATIONAL COMPILATION CENTRE IN ACCORDANCE WITH CAP 242 (PUBLIC HEALTH) REGULATIONS SINCE COVID-19 IS A NOTIFIABLE ILLNESS B) THE panaBIOS TRUSTED TRAVEL DATABASE WHICH GENERATES TRUSTED TRAVEL (TT) CODES & CERTIFICATES FOR INTERNATIONAL TRAVELERS.

Reference intervals

INTERPRETIVE DATA IS PROVIDED ON THE REPORT.

Clinical Utility

COVID 19 DIAGNOSIS, SCREENING

Test Limitations / Confounders

FALSE NEGATIVE RESULTS MAY ARISE E.G. IF: 1) YOU HAVE BEEN TESTED TOO EARLY IN THE ILLNESS. A REPEAT TEST LATER MAY BE POSITIVE. 2) YOU HAVE BEEN TESTED TOO LATE IN THE ILLNESS (PARTIAL RECOVERY PHASE) 3) THE SAMPLE COLLECTION WAS INADEQUATE THEREFORE THERE IS AN INADEQUATE AMOUNT OF TESTING MATERIAL. 4) THERE ARE MUTATIONS IN TARGET GENES. 5) SAMPLES ARE NOT PROPERLY TRANSPORTED OR STORED. FALSE POSITIVE RESULTS (DETECTION OF SARS-COV-2 WHEN ONE DOES NOT HAVE COVID-19) MAY ARISE IF THERE IS CONTAMINATION DURING SAMPLE COLLECTION – SWAB TOUCHES A CONTAMINATED SURFACE.

06 Jun

K-RAS MUTATION, TISSUE BLOCK

June 6, 2023June 6, 2023vincentochiengde

Category

Molecular Genetic Pathology & Cytogenetics

Sub Category

Oncology (Solid Tumors)

Synonym/Aliases

Kras Mutation Analysis; Kras Mutation Detection; Kras Codons 12, 13

Abbreviations

N/A

^Type

Individual Test

^Results

RESULTS READY WITHIN 10 DAYS

^Method

PCR / SEQUENCING

^Temp

KEPT AT ROOM TEMPERATURE

^Setup

BATCHED

Components Parameters

- N/A

PRE-ANALYTIC CONSIDERATIONS

Test Ordering Instructions

FILL OUT TEST REQUEST FORM FULLY & LEGIBLY. CLINICAL HISTORY, HISTOLOGY (H&E) REPORT ARE MANDATORY.

Patient preparation

- N/A

Sample type

TUMOR POSITIVE FORMALIN-FIXED, PARAFFIN-EMBEDDED (FFPE) BLOCK.

Container/ preservative

FORMALIN FIXED, PARAFFIN EMBEDDED BLOCKS [PREFERRED]. ALTERNATIVELY, 5 MICRONS UNSTAINED SECTIONS ON POSITIVELY-CHARGED SLIDES (≥FOUR SLIDES) & 1 MATCHING H&E SLIDE.

Sample volume

SUFFICIENT RESIDUAL TISSUE/ TUMOR MUST BE AVAILABLE ON THE BLOCK

Rejection criteria

LABELING ISSUE (UNLABELED/ MISLABELED); MISSING REQUEST FORM; MISMATCH BETWEEN REQUEST FORM & SAMPLE DETAILS; MISSING AGE/ GENDER; WRONG SAMPLE TYPE; INSUFFICIENT SAMPLE; DECALCIFIED SAMPLES.

Other Instructions

- N/A

Reference intervals

INTERPRETIVE DATA IS PROVIDED ON THE REPORT.

Clinical Utility

DETECTS PRESENCE OR ABSENCE OF KRAS CODON 12/13 (EXON 2) MUTATIONS. A PREDICTIVE/ THERANOSTIC MARKER FOR COLORECTAL & NON-SMALL CELL LUNG CANCER. PATIENTS WITH POSITIVE RESULTS INDICATE RESISTANCE TO ANTI-EGFR THERAPY E.G. CETUXIMAB (ERBITUX), PANITUMUMAB (VECTIBIX).

Test Limitations / Confounders

RESISTANCE TO ANTI-EGFR THERAPY MAY OCCUR DUE TO KRAS CODON 61, BRAF MUTATIONS

06 Jun

KARYOTYPING, BLOOD

June 6, 2023June 6, 2023vincentochiengde

Category

Molecular Genetic Pathology & Cytogenetics

Sub Category

Cytogenetics

Synonym/Aliases

N/A

Abbreviations

N/A

^Type

Individual Test

^Results

RESULTS READY WITHIN 15 - 18 DAYS

^Method

CHROMOSOMAL ANALYSIS VIA CELL CULTURE, EXPOSURE TO MITOGENS, BANDED KARYOGRAMS & MICROSCOPIC ANALYSIS OF METAPHASE CELLS.

^Temp

KEPT AT ROOM TEMPERATURE 1 DAY, 2-8ºC 1 DAY

^Setup

BATCHED

Components Parameters

- N/A

PRE-ANALYTIC CONSIDERATIONS

Test Ordering Instructions

FILL OUT TEST REQUEST FORM FULLY & LEGIBLY. PROVIDE CLINICAL HISTORY. NOTIFY THE LAB PRIOR TO COLLECTION. CONSIDER CHROMOSOMAL MICROARRAY (CMA) AS A POSSIBLE ALTERNATIVE TEST.

Patient preparation

IN CASE OF SELF SAMPLING, MANUFACTURER'S INSTRUCTIONS FOR SELF COLLECTED SPECIMENS APPLY.

Sample type

WHOLE BLOOD OR BONE MARROW IN SODIUM HEPARIN.

Container/ preservative

SODIUM HEPARIN (DARK GREEN TOP) VACUTAINER.

Sample volume

3 ML

Rejection criteria

LABELING ISSUE (UNLABELED/ MISLABELED); MISSING REQUEST FORM; MISMATCH BETWEEN REQUEST FORM & SAMPLE DETAILS; MISSING AGE/ GENDER; WRONG SAMPLE TYPE; INSUFFICIENT SAMPLE.

Other Instructions

AVOID OTHER TYPES OF HEPARIN VACUTAINERS E.G. LITHIUM HEPARIN.

Reference intervals

INTERPRETIVE DATA IS PROVIDED ON THE REPORT.

Clinical Utility

DETECTS NUMERICAL & STRUCTURAL CHROMOSOMAL ABNORMALITIES WITHIN THE ASSAY'S LIMIT OF DETECTION.

Test Limitations/ Confounders

A NORMAL RESULT DOES NOT COMPLETELY EXCLUDE GENETIC DISORDERS E.G. SINGLE GENE DISORDERS, SUBMICROSCOPIC CYTOGENETIC ABNORMALITIES BELOW THE ASSAY'S DETECTION LIMIT.

06 Jun

KARYOTYPING, PRODUCTS OF CONCEPTION (POC)/ STILLBIRTH

June 6, 2023June 6, 2023vincentochiengde

Category

Molecular Genetic Pathology & Cytogenetics

Sub Category

Cytogenetics

Synonym/Aliases

N/A

Abbreviations

N/A

^Type

Individual Test

^Results

RESULTS READY WITHIN 18 - 21 DAYS

^Method

CHROMOSOMAL ANALYSIS VIA CELL CULTURE, EXPOSURE TO MITOGENS, BANDED KARYOGRAMS & MICROSCOPIC ANALYSIS OF METAPHASE CELLS.

^Temp

REFRIGERATE. TIME SENSITIVE THREFORE NOTIFY LAB PRIOR TO COLLECTION & PROMPTLY DELIVER SAMPLE TO THE LAB.

^Setup

BATCHED

Components Parameters

- N/A

PRE-ANALYTIC CONSIDERATIONS

Test Ordering Instructions

FILL OUT TEST REQUEST FORM FULLY & LEGIBLY. PROVIDE CLINICAL HISTORY. NOTIFY THE LAB PRIOR TO COLLECTION. CONSIDER CHROMOSOMAL MICROARRAY (CMA) AS A POSSIBLE ALTERNATIVE TEST.

Patient preparation

IN CASE OF SELF SAMPLING, MANUFACTURER'S INSTRUCTIONS FOR SELF COLLECTED SPECIMENS APPLY.

Sample type

VIABLE FETAL TISSUE/ PRODUCTS OF CONCEPTION (POCs) IN TISSUE CULTURE MEDIA (OR RPMI/ HANK'S/ RINGER'S LACTATE/ NORMAL SALINE TO WHICH 2-3 DROPS OF GENTAMICIN HAVE BEEN ADDED). FIRST TRIMESTER LOSS: POCs IN CULTURE MEDIA OR NORMAL SALINE WITH ANTIBIOTICS. SECOND TRIMESTER AND BEYOND: DUAL SPECIMENS PREFERRED I.E. 1) PLACENTAL BIOPSY FROM FETAL SIDE WITHIN 1 INCH OF THE PLACENTAL INSERTION SITE PLUS 2) FETAL TISSUE (E.G. MUSCLE BIOPSY FROM MEDIAL ASPECT OF THE THIGH OR FETAL TOE).

Container/ preservative

TISSUE BIOPSY IN STERILE CONTAINER CONTAINING TISSUE CULTURE MEDIUM (OR RPMI/ HANK'S/ RINGER'S LACTATE/ NORMAL SALINE TO WHICH 2-3 DROPS OF GENTAMICIN HAVE BEEN ADDED).

Sample volume

EACH BIOPSY SHOULD BE AT LEAST ~5x5 MM (~SIZE OF PENCIL RUBBER/ ERASER) OR LARGER.

Rejection criteria

LABELING ISSUE (UNLABELED/ MISLABELED); MISSING REQUEST FORM; MISMATCH BETWEEN REQUEST FORM & SAMPLE DETAILS; MISSING AGE/ GENDER; WRONG SAMPLE TYPE; INSUFFICIENT SAMPLE; FROZEN SAMPLE.

Other Instructions

IDENTIFY SAMPLES FROM TWINS UNIQUELY WHERE APPLICABLE.

Reference intervals

INTERPRETIVE DATA IS PROVIDED ON THE REPORT.

Clinical Utility

ESTABLISHING CAUSES OF PREGNANCY LOSSES & FETAL ABNORMALITIES ARISING FROM DETECTS NUMERICAL & STRUCTURAL CHROMOSOMAL ABNORMALITIES WITHIN THE ASSAY'S LIMIT OF DETECTION.

Test Limitations/ Confounders

A NORMAL RESULT DOES NOT COMPLETELY EXCLUDE GENETIC DISORDERS E.G. SINGLE GENE DISORDERS, SUBMICROSCOPIC CYTOGENETIC ABNORMALITIES BELOW THE ASSAY'S DETECTION LIMIT.

06 Jun

KARYOTYPING, PRENATAL, AMNIOTIC FLUID/ CHORIONIC VILLUS SAMPLING (CVS)

June 6, 2023June 6, 2023vincentochiengde

Category

Molecular Genetic Pathology & Cytogenetics

Sub Category

Cytogenetics

Synonym/Aliases

N/A

Abbreviations

N/A

^Type

Individual Test

^Results

RESULTS READY WITHIN 18 - 21 DAYS

^Method

CHROMOSOMAL ANALYSIS VIA CELL CULTURE, EXPOSURE TO MITOGENS, BANDED KARYOGRAMS & MICROSCOPIC ANALYSIS OF METAPHASE CELLS.

^Temp

REFRIGERATE. TIME SENSITIVE THREFORE NOTIFY LAB PRIOR TO COLLECTION & PROMPTLY DELIVER SAMPLE TO THE LAB.

^Setup

BATCHED

Components Parameters

- N/A

PRE-ANALYTIC CONSIDERATIONS

Test Ordering Instructions

FILL OUT TEST REQUEST FORM FULLY & LEGIBLY. CLINICAL HISTORY, INDICATION & ULTRASOUND FINDINGS REQUIRED. NOTIFY THE LAB PRIOR TO COLLECTION. CONSIDER CHROMOSOMAL MICROARRAY (CMA) AS A POSSIBLE ALTERNATIVE TEST.

Patient preparation

IN CASE OF SELF SAMPLING, MANUFACTURER'S INSTRUCTIONS FOR SELF COLLECTED SPECIMENS APPLY.

Sample type

CHORIONIC VILLI (1ST TRIMESTER) OR AMNIOTIC FLUID (2ND TRIMESTER).

Container/ preservative

1ST TRIMESTER: CHORIONIC VILLI IN TISSUE CULTURE MEDIA (OR RPMI/ HANK'S/ RINGER'S LACTATE/ NORMAL SALINE TO WHICH 2-3 DROPS OF GENTAMICIN HAVE BEEN ADDED). 2ND TRIMESTER: 20ML AMNIOTIC FLUID IN STERILE FALCON TUBE. ENSURE PROPER, LEAK PROOF CAPPING.

Sample volume

20ML AMNIOTIC FLUID (IN STERILE CONTAINER; DISCARD FIRST 2ML TO AVOID CONTAMINATION WITH MATERNAL CELLS.) / 20MG CHORIONIC VILLI BIOPSY (IN TISSUE CULTURE MEDIA/ NORMAL SALINE WITH GENTAMICIN DROPS).

Rejection criteria

LABELING ISSUE (UNLABELED/ MISLABELED); MISSING REQUEST FORM; MISMATCH BETWEEN REQUEST FORM & SAMPLE DETAILS; MISSING AGE/ GENDER; WRONG SAMPLE TYPE; INSUFFICIENT SAMPLE; FROZEN SAMPLE.

Other Instructions

IDENTIFY SAMPLES FROM TWINS UNIQUELY WHERE APPLICABLE.

Reference intervals

INTERPRETIVE DATA IS PROVIDED ON THE REPORT.

Clinical Utility

DETECTS NUMERICAL & STRUCTURAL CHROMOSOMAL ABNORMALITIES WITHIN THE ASSAY'S LIMIT OF DETECTION.

Test Limitations/ Confounders

A NORMAL RESULT DOES NOT COMPLETELY EXCLUDE GENETIC DISORDERS E.G. SINGLE GENE DISORDERS, SUBMICROSCOPIC CYTOGENETIC ABNORMALITIES BELOW THE ASSAY'S DETECTION LIMIT.

06 Jun

JAK2 V617F MUTATION DETECTION

June 6, 2023June 6, 2023vincentochiengde

Category

Molecular Genetic Pathology & Cytogenetics

Sub Category

Oncology (Hematologic Malignancies)

Synonym/Aliases

JAK2 QUALITATIVE; JAK 2 EXON 14

Abbreviations

JAK 2

^Type

Individual Test

^Results

RESULTS READY WITHIN 14 DAYS

^Method

REAL TIME PCR

^Temp

ROOM TEMPERATURE REFRIGERATE (2-8ºC).

^Setup

BATCHED

Components Parameters

- N/A

PRE-ANALYTIC CONSIDERATIONS

Test Ordering Instructions

FILL OUT TEST REQUEST FORM FULLY & LEGIBLY. CLINICAL HISTORY REQUIRED INCLUDING COMPLETE BLOOD COUNT & BONE MARROW REPORT.

Patient preparation

IN CASE OF SELF SAMPLING, MANUFACTURER'S INSTRUCTIONS FOR SELF COLLECTED SPECIMENS APPLY.

Sample type

WHOLE BLOOD OR BONE MARROW IN EDTA.

Container/ preservative

EDTA (PURPLE TOP) VACUTAINER

Sample volume

3 ML

Rejection criteria

LABELING ISSUE (UNLABELED/ MISLABELED); MISSING REQUEST FORM; MISMATCH BETWEEN REQUEST FORM & SAMPLE DETAILS; MISSING AGE/ GENDER; WRONG SAMPLE TYPE; INSUFFICIENT SAMPLE; CLOTTED SAMPLE, HEMOLYZED SAMPLE

Other Instructions

- N/A

Reference intervals

NEGATIVE/ NOT DETECTED. IN CASE OF A NEGATIVE RESULT WITH A HIGH INDEX OF SUSPICION FOR POLYCYTHEMIA VERA, FOLLOW-UP TESTING FOR JAK2 EXON 12 TESTING SHOULD BE DONE.

Clinical Utility

DIAGNOSIS OF MYELOPROLIFERATIVE NEOPLASMS (MPN) E.G. POLYCYTHEMIA VERA, ESSENTIAL THROMBOCYTHEMIA.

Test Limitations/ Confounders

PRESENCE OF PCR INHIBITORS IN THE SAMPLE MAY PREVENT NUCLEIC ACID AMPLIFICATION. PARADOXICAL RESULTS MAY ARISE DUE TO SELECTION OF INAPPROPRIATE SPECIMEN AND CONTAMINATION DURING SPECIMEN COLLECTION.

1 … 5 6 7 8 9 10